

586 **Supplementary materials**

587

588 **Method and materials (continued)**

589

590 **Safety description**

591 Overall, outcomes related to safety were assessed at any time point and included: any AEFIs,
592 any adverse events (AEs); serious, non-serious and leading to discontinuation, any adverse
593 events of special interest (AESIs), local injection site reactions, local reactions (e.g., erythema,
594 pain or swelling), systemic reactions (e.g. myalgia, rash, abdominal pain, itching, arthralgia,
595 muscle pain, chills, fatigue, fever, headache, nausea, vomiting or diarrhea), any related events,
596 any life-threatening related events, need for medical attention due to adverse reaction (e.g.
597 antipyretic or analgesic treatment, hospitalization, inability to perform daily activities or attend
598 school/work, telehealth consults, attendance to clinic or emergency room or taking medication
599 for side effects), serious adverse events (SAEs) (e.g. chest pain, tachycardia, dyspnea,
600 myocarditis, myopericarditis or severe allergic reactions), non-serious AEs, AEs leading to
601 discontinuation from the study, AEFI by system organ class (SOC) (e.g. infections and
602 infestations; general disorders and administration site conditions; nervous system disorders;
603 sleeping disturbance; musculoskeletal and connective tissue disorders; respiratory, thoracic
604 and mediastinal disorders; cardiac disorders; arrhythmias; injury, poisoning and procedural
605 complications; vascular disorders; haemorrhagic diseases; thromboembolism; reproductive
606 system and breast disorders; hepato-renal syndrome; gastrointestinal disorders or psychiatric
607 disorders), unsolicited or unbalanced AEFIs (e.g. autoimmune diseases, Guillain-Barré
608 syndrome; acute aseptic arthritis or Bell's palsy), hypersensitivity, lymphadenopathy and
609 death. Then, we classified all adverse events as local and systemic AEFI, serious AEFI, AESI,
610 health impact, and unsolicited AEFI by SOC following any dose of BNT162b2 in adolescents
611

612 **Data extraction and management**

613 Study characteristics and outcomes data were extracted by a single reviewer and crosschecked
614 by a second reviewer to ensure consistency. Extractions were conducted using a pre-piloted
615 extraction form set up in Covidence, which included the following fields: (1) identification of
616 the study: country in which the study was conducted and time period over which the study was
617 conducted, (2) methods: aim of the study and study design, participants-mean age and age
618 group of participants included in the study, total number of participants included, number of

619 participants per group (if reported), (3) interventions: follow-up period after vaccine
 620 administration (first and second dose), primary doses or booster administered and (4) safety
 621 outcomes: type of AEFI and number of events in each group and sub-age-group as well. (5)
 622 neutralising antibodies (type, titter and time) and (6) Level of efficacy of effectiveness
 623 (proportion and period of time after vaccination). At any point of time, discrepancies were
 624 resolved through consensus or adjudication by a senior review author. A Characteristics of
 625 included studies table was completed using descriptive information extracted from studies and
 626 exported into excel sheet from Covidence.

627

628 **Supplementary tables and box**

629 **Supplementary Table 1: Definition of Safety Outcome (adapted from Wu et al)**
 630

Outcome	Definition
Adverse event following immunization (AEFI)	An AEFI is any untoward medical occurrence which follows immunization and which does not necessarily have a causal relationship with the usage of the vaccine. The adverse event may be any unfavourable or unintended sign, abnormal laboratory finding, symptom or disease.
Serious adverse events (SAE)	A serious adverse event is any untoward medical occurrence that at any dose results in death, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, or is life-threatening.
Solicited adverse events	Solicited adverse events include prospectively self-collected occurrences of local and systemic reactions. Participants were usually asked to monitor and record local reactions, systemic events, and antipyretic medication usage for 7 days following each administration.
Local reactions	Local reactions included pain at the injection site, redness, swelling, induration, etc.
Systemic reactions	Systemic reactions included headache, myalgia, fever, fatigue, vomiting, diarrhea, muscle pain, etc.
Unsolicited adverse events	Unsolicited AEs would be represented in the AE domain unless they were classified as solicited adverse event.
Adverse event of special interest (AESI)	An adverse event of special interest (serious or non-serious) is one of scientific and medical concern specific to vaccine, for which ongoing monitoring can be appropriate.
Withdrawal due to adverse events	The number of participants reported as withdrawn from clinical trial due to adverse events whether related to study intervention or not.
Death	The number of participants reported for death regardless of causality.

631

632

633

634

635 **Supplementary Table 2: Characteristic of included studies**

Study ID, settings, design and average age of participants	Condition	Objective	Dose type	Outcomes of Interest	Event in immunocompromised	Total in immunocompromised	Event Control	Total Control	Time	Mean (SE) in AU/ml/Immunocompromised	Total Immunocompromised	Mean (SE) in Au/ml Control	Total Control	Authors conclusion
Akgun et al., 2022/Turkey, Prospective cohort of 15.4 ± 1.5 years	Rheumatic diseases	To examine vaccine antibody response of children and adolescents with rheumatic diseases in relation to confounding factors. To evaluate systemic and local side effects of the BNT162b2 mRNA vaccine in children with paediatric rheumatic diseases.	Dose 1	Pain	24	41								Paediatric rheumatic diseases patients receiving immunomodulatory treatments were able to mount an effective humoral response after two dose regimens of BNT162b2 mRNA vaccine safely without interrupting their current treatments.
				Swelling	2	41								
				Erythema	1	41								
				Fever	5	41								
				Muscles aches	6	41								
				Headaches	10	41								
			Dose 2	Pain	20	41								
				Swelling	2	41								

				Erythema	1	41							
				Fever	6	41							
				Muscles aches	7	41							
				Headaches	11	41							
				Fatigue	12	41							
Bekenstein et al., 2022/Israel and Slovenia, Prospective cohort study, adolescents (12–	Rheumatic diseases	To explore safety and immunogenicity of the mRNA COVID-19 vaccine among	Dose 1	Pain	64	88							

Evidence of good short-term vaccine safety and adequate humoral immune

18 years) and young adults (18–21 years)		adolescents with juvenile-onset AIIRDs treated with immunomodulatory medications and compared it with the results among healthy children	Swelling	8	88								response in the unique population of adolescents with juvenile-onset AIIRDs.	
			Erythema	2	88									
			Itching	3	88									
			Pruritus	1	88									
			Fever	14	88									
			Vomiting	2	88									
			Nausea	6	88									
			Running nose	4	88									
			Muscles aches	19	88									
			Joint pain	10	88									
			Chills	11	88									
			Headache	22	88									
			Feeling unwell	24	88									
			Weakness	25	88									
			Fatigue	29	88									
Exacerbation	1	88												
	Dose 2	Antibody seropositivity	36	37	22	22	3 months							
		IgG dosage					3 months	93.07 (52.46)	37	149.15 (22.04)	22			
Dimopoulou et al., 2022/Greece, Single-center, cohort study of 17 (16–21) years	Rheumatic diseases	To evaluate safety and tolerability of BNT162b2 COVID-19 vaccine in adolescents	Dose 2	Pain	21	42							mRNA vaccines appear to be safe and well tolerated in adolescents with JIA receiving treatment with TNF inhibitors	
				Swelling	12	42								
				Erythema	31	42								

				Muscles aches	5	42															
				Joint pain	5	42															
				Headache	7	42															
				Fatigue	6	42															
Haslak et al., 2021/Turkey, Cross-sectional study, of 15.34 (12.02-20.92)	Rheumatic diseases	To examine vaccine related adverse events of BNT162b2 messenger COVID-19 vaccine	Dose 1	Fever	14	191												Acceptable safety profile of COVID-19 vaccines and encouragement of children with IRD to be vaccinated.			
				Vomiting	23	191															
				Nausea	2	191															
				Headache	10	191															
			Dose 2	Fatigue	25	191															
				Fever	12	191															
				Vomiting	6	191															
				Headache	14	191															
King et al., 2022/UK, Prospective cohort of 12-15 years	Neurodisabilities	To inform the risk-benefit for subsequent COVID-19 vaccinations	Dose 1	Erythema	1	26												Mild/moderate adverse reactions except for one child			
				Fever	3	26															
				Feeling unwell	10	26															
				Fatigue	19	26															
			Dose 2	Erythema	2	22															
				Fever	3	22															
				Feeling unwell	3	22															
				Fatigue	6	22															

Valentini et al., 2022/Italy, Prospective cohort of 17.90 (±4.59)	Down syndrome	To evaluate the safety of mRNA vaccination in individuals with DS. To measure SARS-CoV-2 specific antibodies over time. To correlate humoral immune response of individuals with DS with those of the healthy controls (HC)	Dose 1	Pain	10	40							Individuals with DS exhibit a good humoral response to the BNT162b2 vaccine; however, similarly to in HC, the immune response wanes over time.
				Erythema	1	40							
				Fever	2	40							
				Muscles aches	1	40							
				Chills	1	40							
				Headache	1	40							
				Fatigue	1	40							
				Antibody seropositivity	39	40	36	36					
				Dose 2	Pain	10							
			Erythema		2								
			Fever		4								
			Muscles aches		1								
			Headache		1								
			Fatigue		2								
			Dose 1	IgG dosage					21 days	14.29(7.68)	40	51.27(71.03)	36
									28 days	1164.51(1153.39)	40	2595.47(1273.92)	36
									180 days	1100(153.78)	40	953.31(193.01)	36
			Dose 2	IgG dosage					21 days	107.26(76.89)	40	164.87(169.85)	36
									28 days	107.26(76.89)	40	800(30.88)	36
									180 days	143.55(84.58)	40	143.55(84.93)	36

Michos et al., 2022/Italy, Prospective cohort of 19.6 (17.6–24.3)	Cystic fibrosis	To investigate immunogenicity of SARS-CoV-2 BNT162b2 vaccine and its association with epidemiological and clinical parameters in a cohort of CF patients and to compare it with a cohort of healthy individuals	Dose 1	Antibody seropositivity	27	33	38	66					BNT162b2 vaccine appears to be immunogenic with limited adverse events in CF population.	
			Dose 2	Antibody seropositivity	32	33	63	66	1 month					
			Dose 1	IgG dosage						222.45(116 2.05)	33	35.31(105.75)		66
Piccini et al., 2022/Italy, Retrospective study, 18.4 ± 2.4	Type 1 diabetes	To evaluate adverse effects, possible glycemic control modification and temporary insulin dose adjustment in youth with T1D, users of different levels of technology, who completed a whole COVID-19 vaccination cycle	Dose 1	Pain	28	39							Vaccination not associated to significant perturbation of glycemic control in adolescents and young adults with T1D, and, if elevation of glucose values occurs, it is mild, transient, tolerable and not requiring insulin dose adjustment. Side effects are mild and similar to those reported in the general population. All in all, this information could be of clinical use when counseling families in order to reassure them about SARS-CoV-2 vaccination in youth with T1D. Preliminary experience with RNA vaccines in AYA with	
				Fever	5	39								
				Muscles aches	5	39								
				Headache	7	39								
			Dose 2	Weakness	16	39								
				Pain	25	39								
				Fever	10									
				Muscles aches	5	39								
				Headache	12	39								
Weakness	17	39												
Riviere et al., 2021/France, Retrospective	Solid tumour	To evaluate safety and efficacy of BNT162b2 vaccine in	Dose 1	Pain	6	13								

study, Median: 17 years	adolescents and young adults (AYA) with solid tumour.	Fever	2	13							solid tumours and report a good safety profile and excellent immunogenicity	
		Headache	1	13								
		Fatigue	2	13								
		Dose 2	Pain	2	13							
			Fever	4	13							
			Vomiting	1	13							
			Fatigue	5	13							

636

637

638 **Supplementary Table 3: Risk of bias in included studies (ROBINS-I)**

639

Domain		Akgün 2022 (cohort)	Dimopoulou 2022 (cohort)	Haslak 2022 (cross-sectional)	Heshin-Bekenstein 2022 (controlled cohort)	King 2022 (cohort/active surveillance)	Michos 2022 (controlled cohort)	Piccini 2022 (retrospective cohort)	Riviere 2021 (retrospective cohort)	Valentini 2022 (controlled cohort)
Bias due to confounding	Judgment	Unclear	Low	Low	High	Unclear	High	Unclear	Unclear	High
	Supporting text	Efficacy results are stratified by diagnoses and treatments. Safety results do not appear to be stratified.	Safety results are analysed by type of diagnosis and treatments.	Safety results are analysed by type of diagnosis, treatments, and other demographic characteristics.	Efficacy results are stratified by treatments, no adjustment for confounders reported, however, age-matching was identified by authors as sub-optimal since controls were younger than participants with rheumatic disease. Safety results do not appear to be stratified or adjusted for confounders.	Safety results are not stratified.	Efficacy results are analysed by demographic and clinical characteristics, no adjustment for confounders reported. A lack of age and gender matching was reported by the authors. Safety results do not appear to be stratified or adjusted.	Safety results are not stratified.	Efficacy and safety results are not stratified.	Efficacy results are analysed by demographic and clinical characteristics, no adjustment for confounders reported. Authors identified the lack of age-matched controls as a limitation. Safety results do not appear to be stratified or adjusted.
Bias in selection of participants into the study	Judgment	Unclear	Unclear	Unclear	Unclear	Unclear	Unclear	Unclear	Unclear	Unclear
	Supporting text	Patients were invited by phone call – it is unclear	Insufficient information on	Data were captured by web-based	Insufficient information on recruitment of	Clinician-identified patients were invited	Insufficient information on recruitment of	Insufficient information on inclusion into	Insufficient information on recruitment.	Insufficient information on recruitment of

Domain		Akgün 2022 (cohort)	Dimopoulou 2022 (cohort)	Haslak 2022 (cross-sectional)	Heshin-Bekenstein 2022 (controlled cohort)	King 2022 (cohort/active surveillance)	Michos 2022 (controlled cohort)	Piccini 2022 (retrospective cohort)	Riviere 2021 (retrospective cohort)	Valentini 2022 (controlled cohort)
		whether volunteer bias may be present.	recruitment. Informed consent was sought, volunteer bias could not be ruled out.	survey, with no information on recruitment – it is unclear whether volunteer bias may be present.	patients with rheumatic disease as well as healthy controls. These groups were recruited from different centres. Informed consent was sought.	following informed medical consent. It is unclear whether volunteer bias may be present.	patients with cystic fibrosis as well as healthy controls. These groups were systematically different as controls were healthcare workers. Informed consent was sought.	this retrospective study.	Informed consent was sought, volunteer bias could not be ruled out.	patients with Down syndrome as well as healthy controls. These groups were systematically different as controls were healthcare workers. Informed consent was sought.
Bias in classification of interventions	Judgment	Low	Low	Unclear	Low	Low	Unclear	Unclear	Low	Unclear
	Supporting text	Patients were vaccinated with the BNT162b2 mRNA vaccine post-recruitment.	Patients were vaccinated with the BNT162b2 mRNA vaccine post-recruitment.	Vaccination status was verified by phone calls and national registries, however, two types of COVID-19 vaccine was available. It is not clear how the type of vaccine received was determined.	Patients were vaccinated with the BNT162b2 mRNA vaccine post-recruitment.	Patients were vaccinated with the BNT162b2 mRNA vaccine post-recruitment.	Authors report that both groups were vaccinated with the BNT162b2 mRNA vaccine. It is unclear if this was post-recruitment, or whether vaccination status was confirmed.	It is not reported how vaccination status was verified.	Patients were vaccinated with the BNT162b2 mRNA vaccine post-recruitment.	Authors report that both groups were vaccinated with the BNT162b2 mRNA vaccine. It is unclear if this was post-recruitment, or whether vaccination status was confirmed.
Bias due to deviations from intended interventions	Judgment	Unclear	Unclear	Low	Unclear	Unclear	Unclear	Unclear	Unclear	Unclear
	Supporting text	It is not reported whether – or how - vaccination status of participants was determined.	It is not reported how vaccination status of participants was determined.	Vaccination status was verified by phone calls and national registries.	It is not reported whether – or how - vaccination status of participants was determined.	It is not reported whether – or how - vaccination status of participants was determined.	Authors report that both groups were vaccinated with the BNT162b2 mRNA vaccine. It is unclear if this was post-recruitment, or whether vaccination status was confirmed.	It is not reported how vaccination status of participants was determined.	It is not reported whether – or how - vaccination status of participants was determined.	Authors report that both groups were vaccinated with the BNT162b2 mRNA vaccine. It is unclear if this was post-recruitment, or whether vaccination status was confirmed.
Bias due to missing data	Judgment	Unclear	Unclear	Low	High	Unclear	Unclear	Unclear	Low	Low
	Supporting text	No withdrawals or loss to follow up is reported, but some investigator-driven exclusions, e.g. exclusion of patients without complete	No details on how many participants were potentially eligible, therefore attrition could not be assessed.	A total of 39/285 potentially eligible patients (14%) were excluded, but with reasons that were considered reasonable.	Approximately 3% loss to follow-up in the group with rheumatic disease following the second dose, with no loss to follow-up in the control group. High attrition for/low availability of	No details on how many participants were potentially eligible, therefore attrition could not be assessed.	No withdrawals or loss to follow up is reported, but some investigator-driven exclusions are implied, e.g. exclusion of patients without full vaccination. This does not align with	No withdrawals or loss to follow up is reported, but some investigator-driven exclusions are implied, e.g. inclusion of only patients	Approximately 23% loss to follow-up, but for valid reasons, and no investigator-driven exclusions are reported.	No withdrawals or loss to follow up is reported and investigator-driven exclusion of individuals with Down syndrome, for the presence of antibodies at baseline, is

Domain		Akgün 2022 (cohort)	Dimopoulou 2022 (cohort)	Haslak 2022 (cross-sectional)	Heshin-Bekenstein 2022 (controlled cohort)	King 2022 (cohort/active surveillance)	Michos 2022 (controlled cohort)	Piccini 2022 (retrospective cohort)	Riviere 2021 (retrospective cohort)	Valentini 2022 (controlled cohort)
		vaccination schedule (14% of total sample), do not align with the review question.			immunogenicity data (41% in rheumatic disease group and 55% in the control group provided data) due to limited availability of serum samples. No further exclusions reported.		the review question, though its impact could not be numerically assessed.	who underwent a whole vaccination cycle. This does not align with the review question, though its impact could not be numerically assessed.		considered reasonable.
Bias in measurement of outcomes	Judgment	Unclear	Unclear	Unclear	High	Unclear	Unclear	Unclear	Unclear	Unclear
	Supporting text	Efficacy outcomes were clearly defined and laboratory-determined, with minimal risk of ascertainment bias. Safety outcomes were participant-reported, using a structured questionnaire; while this may have introduced bias this would not be differential, given the single-arm design.	Safety outcomes were participant-recorded, using a diary card; while this may have introduced bias this would not be differential, given the single-arm design.	It is not clear whether safety was objectively assessed: ‘...experienced adverse events of the participants were verified by phone calls and national registries.’	Efficacy outcomes were clearly defined and laboratory-determined, with minimal risk of ascertainment bias. Safety outcomes, however, were participant-reported using a telephonic questionnaire. Given the controlled nature of the study, this may have biased measures of association.	Parents were asked to record side effects in a diary and were followed up with a telephone call; while this may have introduced bias this would not be differential, given the single-arm design.	Efficacy outcomes were clearly defined and laboratory-determined, with minimal risk of ascertainment bias. Safety outcomes were participant-reported; while this may have introduced bias this would not be differential, given the single-arm safety comparison.	Symptoms after first and second dose recorded in medical files were retrospectively investigated, either face to face or via telemedicine.	Efficacy outcomes were clearly defined and laboratory-determined, with minimal risk of ascertainment bias. Safety outcomes were participant-reported; while this may have introduced bias this would not be differential, given the single-arm design.	Efficacy outcomes were clearly defined and laboratory-determined, with minimal risk of ascertainment bias. Safety outcomes were participant-reported; while this may have introduced bias this would not be differential, given the single-arm safety comparison.
Bias in selection of the reported result	Judgment	Unclear	Unclear	Unclear	Unclear	Unclear	Unclear	Unclear	Unclear	Unclear
	Supporting text	We did not have access to the protocol, therefore selective reporting could not be assessed.	We did not have access to the protocol, therefore selective reporting could not be assessed.	We did not have access to the protocol, therefore selective reporting could not be assessed.	We did not have access to the protocol, therefore selective reporting could not be assessed.	We did not have access to the protocol, therefore selective reporting could not be assessed.	We did not have access to the protocol, therefore selective reporting could not be assessed.	We did not have access to the protocol, therefore selective reporting could not be assessed.	We did not have access to the protocol, therefore selective reporting could not be assessed.	We did not have access to the protocol, therefore selective reporting could not be assessed.
Other source of bias	Judgment	Unclear	Low	Unclear	Unclear	Low	Unclear	Low	Unclear	Unclear
	Supporting text	Lack of control group, small sample size, short	None identified.	Details on medication doses, duration of treatment and	Disease diversity limited conclusions regarding the effect of	None identified.	Limited numbers of patients with cystic fibrosis.	None identified.	Small sample size, patients were limited to those with solid	Small sample size.

Domain		Akgün 2022 (cohort)	Dimopoulou 2022 (cohort)	Haslak 2022 (cross-sectional)	Heshin-Bekenstein 2022 (controlled cohort)	King 2022 (cohort/active surveillance)	Michos 2022 (controlled cohort)	Piccini 2022 (retrospective cohort)	Riviere 2021 (retrospective cohort)	Valentini 2022 (controlled cohort)
		post-vaccine follow-up.		disease activity not available. Some groups with vaccine effect-modifying characteristics were grouped together.	immunomodulatory medication and disease type on efficacy.				tumours limiting generalisability to all paediatric oncology patients, short post-vaccine follow-up.	
Overall bias	Judgment	Unclear	Unclear	Unclear	High	Unclear	High	Unclear	Unclear	High
	Supporting text	Bias due to confounding and deviations from intended interventions as well as selection bias, attrition bias, ascertainment bias and selective outcome reporting could not be ruled out. Several other limitations were identified.	Bias due to deviations from intended interventions as well as selection bias, attrition bias, ascertainment bias and selective outcome reporting could not be ruled out.	Selection bias, classification bias, ascertainment bias, and selective outcome reporting could not be ruled out. Several other limitations were identified.	High risk of confounding, attrition bias and ascertainment bias. Bias due to deviations from intended interventions as well as selection bias and selective outcome reporting could not be ruled out. Several other limitations were identified.	Bias due to confounding and deviations from intended interventions as well as selection bias, attrition bias, ascertainment bias and selective outcome reporting could not be ruled out.	High risk of confounding. Selection bias, classification bias, deviation from intended interventions, attrition bias, ascertainment bias, and selective outcome reporting could not be ruled out. Other limitations were also identified.	Confounding, selection bias, classification bias, deviation from intended interventions, attrition bias, ascertainment bias, and selective outcome reporting could not be ruled out.	Confounding, selection bias, deviation from intended interventions, ascertainment bias, and selective outcome reporting could not be ruled out. Several other limitations were identified.	High risk of confounding. Selection bias, classification bias, deviation from intended interventions, ascertainment bias, and selective outcome reporting could not be ruled out. Other limitations were also identified.

640

641

642

643 **Supplementary box 1: Search terms built for MEDLINE (PubMed)**

644

645

646

("COVID-19"[Mesh] OR "SARS-CoV-2"[Mesh] OR "COVID-19 Vaccines"[Mesh] OR "COVID-19 Serological Testing"[Mesh] OR "COVID-19 Nucleic Acid Testing"[Mesh] OR "SARS-CoV-2 variants" [Supplementary Concept] OR "COVID-19 drug treatment" [Supplementary Concept] OR "COVID-19 serotherapy" [Supplementary Concept] OR "2019-nCoV" OR "2019nCoV" OR "cov 2" OR "Covid-19" OR "sars coronavirus 2" OR "sars cov 2" OR "SARS-CoV-2" OR "severe acute respiratory syndrome coronavirus 2" OR "coronavirus 2" OR "COVID 19" OR "COVID-19" OR "2019 ncov" OR "2019nCoV" OR "corona virus disease 2019" OR "cov2" OR "COVID-19" OR "COVID19" OR "nCov 2019" OR "nCoV" OR "new corona virus" OR "new coronaviruses" OR "novel corona virus" OR "novel coronaviruses" OR "SARS Coronavirus 2" OR "SARS2" OR "SARS-COV-2" OR "Severe Acute Respiratory Syndrome Coronavirus 2")

AND

(BNT162b2[All Fields] OR Pfizer-BioNTech[All Fields] OR Pfizer/BioNTech[All Fields] OR Comirnaty[All Fields])

AND

(tolerability[Title/Abstract] OR reactogenicity[Title/Abstract] OR safe*[Title/Abstract] OR side effect[Title/Abstract] OR adverse event[Title/Abstract] OR adverse effect[Title/Abstract] OR adverse reaction[Title/Abstract] OR adverse OR efficacy[Title/Abstract] OR effectiveness[Title/Abstract] OR outcome[Title/Abstract] OR undesirable effect*[Title/Abstract] OR treatment emergent[Title/Abstract] OR toxicity[Title/Abstract])

AND

("Adolescent"[Mesh] OR "Adolescen*" [Title/Abstract] OR "Teen*" [Title/Abstract] OR "Youth*" [Title/Abstract] OR "juvenile*" [Title/Abstract] OR "puberty" [Title/Abstract] OR "young*" [Title/Abstract] OR "Child" [Mesh] OR "child*" [Title/Abstract] OR "Pediatrics" [Mesh])